CY1107773T1 - Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη - Google Patents

Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη

Info

Publication number
CY1107773T1
CY1107773T1 CY20071101361T CY071101361T CY1107773T1 CY 1107773 T1 CY1107773 T1 CY 1107773T1 CY 20071101361 T CY20071101361 T CY 20071101361T CY 071101361 T CY071101361 T CY 071101361T CY 1107773 T1 CY1107773 T1 CY 1107773T1
Authority
CY
Cyprus
Prior art keywords
extinskiden
discarchate
standardizations
formulations
methods
Prior art date
Application number
CY20071101361T
Other languages
English (en)
Inventor
Salve Pilar Calvo
Barreira Maria Tobio
Bastiaan Nuijen
Jacob Hendrik Beijnen
Original Assignee
Pharma Mar S.A., Sociedad Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107773(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar S.A., Sociedad Unipersonal filed Critical Pharma Mar S.A., Sociedad Unipersonal
Publication of CY1107773T1 publication Critical patent/CY1107773T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Παρέχονται τυποποιήσεις εκτεϊνασκιδίνης, μέθοδοι παρασκευής της ιδίας, αντικείμενα κατασκευής και εξοπλισμοί με τέτοιες τυποποιήσεις και μέθοδοι θεραπείας πολλαπλασιαστικών ασθενειών με τις ίδιες τυποποιήσεις.
CY20071101361T 2004-10-29 2007-10-22 Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη CY1107773T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29
EP05077333A EP1658848B1 (en) 2004-10-29 2005-10-12 Formulations comprising ecteinascidin and a disaccharide

Publications (1)

Publication Number Publication Date
CY1107773T1 true CY1107773T1 (el) 2013-06-19

Family

ID=35432682

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101361T CY1107773T1 (el) 2004-10-29 2007-10-22 Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη

Country Status (37)

Country Link
US (2) US8895557B2 (el)
EP (1) EP1658848B1 (el)
JP (1) JP4268163B2 (el)
KR (1) KR101188691B1 (el)
CN (2) CN102018714B (el)
AR (2) AR051653A1 (el)
AT (1) ATE368461T1 (el)
AU (1) AU2005227421B2 (el)
BR (1) BRPI0517238B1 (el)
CA (1) CA2520979C (el)
CY (1) CY1107773T1 (el)
DE (1) DE602005001833T2 (el)
DK (1) DK1658848T3 (el)
ES (1) ES2290844T3 (el)
GT (1) GT200500314A (el)
HK (1) HK1091724A1 (el)
HN (1) HN2005029978A (el)
HR (1) HRP20070374T3 (el)
IL (1) IL182776A (el)
JO (1) JO2464B1 (el)
MX (1) MXPA05011650A (el)
MY (1) MY139049A (el)
NO (1) NO328035B1 (el)
NZ (1) NZ554761A (el)
PA (1) PA8650801A1 (el)
PE (2) PE20100089A1 (el)
PL (1) PL1658848T3 (el)
PT (1) PT1658848E (el)
RS (1) RS50510B (el)
RU (1) RU2382647C2 (el)
SI (1) SI1658848T1 (el)
SV (1) SV2006002283A (el)
TW (1) TWI296523B (el)
UA (1) UA91032C2 (el)
UY (1) UY29183A1 (el)
WO (1) WO2006046079A1 (el)
ZA (1) ZA200703450B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) * 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
JP4554684B2 (ja) * 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
KR101716804B1 (ko) 2010-11-12 2017-03-15 파르마 마르 에스.에이. 항종양 알칼로이드를 이용한 병용요법
LT3656393T (lt) * 2011-04-28 2022-12-12 Oncopeptides Ab Liofilizuoti citotoksinių dipeptidų preparatai
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
US10610529B2 (en) * 2016-02-04 2020-04-07 Jiangsu Hengrui Medicine Co., Ltd. Trabectedin-inclusive injectable pharmaceutical composition for gastrointestinal external use and a method for manufacturing the same
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
EP4061372A1 (en) * 2019-11-21 2022-09-28 Pharma Mar, S.A. Methods of treating small cell lung cancer with lurbinectedin formulations
KR20230002462A (ko) 2020-04-15 2023-01-05 에버 발린젝트 게엠베하 트라벡테딘 및 아미노산을 포함하는 조성물
US20230226051A1 (en) * 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
ATE69234T1 (de) * 1986-06-09 1991-11-15 Univ Illinois Ekteinascidine 729, 743, 745, 759a, 759b and 770.
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) * 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
JP4562815B2 (ja) 1997-05-21 2010-10-13 ジェネンテック， インコーポレイテッド トロンボポエチンの新規な投与
CZ301083B6 (cs) 1998-04-06 2009-11-04 The Board Of Trustees Of The University Of Illinois Ekteinascidinová sloucenina, farmaceutický prostredek ji obsahující a její použití
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
US7247892B2 (en) * 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) * 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
CA2418320A1 (en) * 2000-08-11 2002-02-21 City Of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
AU2002210749B2 (en) * 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
JP2004529074A (ja) 2000-11-03 2004-09-24 プレジデント アンド フェロウズ オブ ハーバード カレッジ サフラマイシン、そのアナログ、およびその使用
CZ20031327A3 (cs) * 2000-11-06 2003-11-12 Pharma Mar, S. A. Užití ET-743 k výrobě léků pro účinnou protinádorovou léčbu
PL367260A1 (en) * 2001-01-25 2005-02-21 Bristol-Myers Squibb Company Parenteral formulation containing epothilone analogs
WO2002064843A1 (en) * 2001-02-09 2002-08-22 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
CZ20032266A3 (cs) 2001-03-06 2004-02-18 Bristol-Myers Squibb Company Dávkovací formy pro ošetřování nádorů
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
US20050004018A1 (en) * 2001-10-19 2005-01-06 Jose Jimeno Use of antitumoral compound in cancer therapy
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
WO2005049031A1 (en) 2003-11-13 2005-06-02 Pharma Mar, S.A.U. Combination
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
AU2005261860A1 (en) * 2004-07-09 2006-01-19 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of BRCA1
JP2008514688A (ja) * 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
JP4554684B2 (ja) 2004-10-26 2010-09-29 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗癌治療
KR101188691B1 (ko) 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
EP1962843B1 (en) * 2005-11-25 2011-02-23 Pharma Mar S.A., Sociedad Unipersonal Use of parp-1 inhibitors
AU2007249281A1 (en) * 2006-05-12 2007-11-22 Pharma Mar, S.A. Anticancer treatments with a combination of docetaxel and ecteinascidin

Also Published As

Publication number Publication date
CA2520979A1 (en) 2006-02-15
UY29183A1 (es) 2006-05-31
ZA200703450B (en) 2008-09-25
US20150094313A1 (en) 2015-04-02
IL182776A (en) 2010-06-30
RU2382647C2 (ru) 2010-02-27
PL1658848T3 (pl) 2007-12-31
PA8650801A1 (es) 2006-09-22
IL182776A0 (en) 2007-08-19
EP1658848B1 (en) 2007-08-01
AR110986A2 (es) 2019-05-22
SV2006002283A (es) 2006-07-20
AR051653A1 (es) 2007-01-31
GT200500314A (es) 2007-03-22
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
ATE368461T1 (de) 2007-08-15
CN1823794A (zh) 2006-08-30
BRPI0517238A (pt) 2008-10-07
NO20072713L (no) 2007-07-19
JP4268163B2 (ja) 2009-05-27
HN2005029978A (es) 2009-10-27
HK1091724A1 (en) 2007-01-26
SI1658848T1 (sl) 2007-12-31
BRPI0517238B1 (pt) 2021-11-09
PT1658848E (pt) 2007-11-05
DE602005001833D1 (de) 2007-09-13
HRP20070374T3 (en) 2007-10-31
AU2005227421B2 (en) 2007-06-28
US8895557B2 (en) 2014-11-25
KR101188691B1 (ko) 2012-10-09
TW200621256A (en) 2006-07-01
DE602005001833T2 (de) 2008-04-17
ES2290844T3 (es) 2008-02-16
TWI296523B (en) 2008-05-11
DK1658848T3 (da) 2007-11-26
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
CN102018714A (zh) 2011-04-20
PE20100089A1 (es) 2010-03-01
UA91032C2 (en) 2010-06-25
EP1658848A1 (en) 2006-05-24
US20060094687A1 (en) 2006-05-04
WO2006046079A1 (en) 2006-05-04
RS50510B (sr) 2010-03-02
CN102018714B (zh) 2014-01-08
CA2520979C (en) 2009-03-24
NZ554761A (en) 2010-01-29
US10322183B2 (en) 2019-06-18
JO2464B1 (en) 2009-01-20
JP2006124393A (ja) 2006-05-18
MXPA05011650A (es) 2006-05-17
PE20060925A1 (es) 2006-10-23
AU2005227421A1 (en) 2006-05-18

Similar Documents

Publication Publication Date Title
CY1107773T1 (el) Τυποποιησεις που περιεχουν εκτεïνασκιδινη και δισακχαριτη
CY1120257T1 (el) ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3b]ΠΥΡΙΜΙΔΙΝ-4-ΥΛΑΜΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ JANUS
CY1118760T1 (el) Τροποποιημενα αντισωματα εναντι il-23
ATE407967T1 (de) Nukleierungsmittel
CY1119601T1 (el) Προαγωγεις αποπτωσης
MY198605A (en) Maytansinoid derivatives conjugates thereof, and methods of use
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
CY1108544T1 (el) Παραγωγα πυραζολιου, συνθεσεις που περιεχουν τετοιες ενωσεις και μεθοδοι χρησης
TW200732349A (en) Anti-OX40L antibodies and methods using same
ATE461217T1 (de) Glp-1-verbindungen
CY1105137T1 (el) Παραγωγα αμινοκυκλοεξυλ αιθερων και χρησεις τους
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
WO2004034990A3 (en) Methods and compositions for use in treating cancer
CL2011000729A1 (es) Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
HK1097828A1 (en) 42-0-alkoxyalkyl rapamycin derivatives and compositions comprising same
NO20062420L (no) Anvendelse av IAP-oligomer og et kjemoterapeutisk middel for behandling av proliferative sykdommer
DE602005011780D1 (de) Triazinderivate mit carbamatfunktion
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO20082425L (no) Formuleringer omfattende jorumycin-, reni-eramycin-, safracin- eller saframycin-relaterte forbindelser for behandling av proliferative sykdommer
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
CL2007002671A1 (es) Compuestos derivados de octahidro-pirrolo[3,4-c]pirrol; composicion farmaceutica que la comprende; y uso del compuesto en el tratamiento del vih, sida o arc.
CY1111285T1 (el) Θεραπεια αυτοανοσων ασθενειων
SE0301650D0 (sv) Novel compounds
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
NO20053903D0 (no) Nukleotidlipidesterderivater.